Clinuvel Pharmaceuticals Ltd: Ceasing to be a substantial holder
Clinuvel Pharmaceuticals Ltd: Becoming a substantial holder
Clinuvel Pharmaceuticals Ltd: Vitiligo and Operational Update
Clinuvel Pharmaceuticals Ltd: Annual Results Webinar
Clinuvel Pharmaceuticals Ltd: Ceasing to be a substantial holder
Clinuvel Pharmaceuticals Ltd: Becoming a substantial holder
Clinuvel Pharmaceuticals Ltd: Ceasing to be a substantial holder
Clinuvel Pharmaceuticals Ltd: Becoming a substantial holder
Clinuvel Pharmaceuticals Ltd: Change of Company Secretary
Clinuvel Pharmaceuticals Ltd: Ceasing to be a substantial holder
Clinuvel Pharmaceuticals Ltd: Becoming a substantial holder
Clinuvel Pharmaceuticals Ltd: Notification of cessation of securities - CUV
Clinuvel Pharmaceuticals Ltd: Afamelanotide Assists DNA Repair Response Following UVR
Clinuvel Pharmaceuticals Ltd: CLINUVEL extends Managing Director Employment Agreement
Clinuvel Pharmaceuticals Ltd: Change of Company Secretary
Clinuvel Pharmaceuticals Ltd: SCENESSE European Orphan Drug Designation for VP
Clinuvel Pharmaceuticals Ltd: afamelanotide in fair-skinned Parkinsons patients
Clinuvel Pharmaceuticals Ltd: CLINUVEL Newsletter III - June 2024
Clinuvel Pharmaceuticals Ltd: Update - Notification of buy-back - CUV
Clinuvel Pharmaceuticals Ltd: CLINUVEL withdraws label expansion for adolescent EPP
No Data